Platelets Operational Efficiency
Streamline operations while reducing the risk of TTI and TA-GVHD with the INTERCEPT Blood System for Platelets, pathogen reduction system.
The INTERCEPT Blood System can streamline operations throughout the donor-transfusion chain while providing significant clinical benefits via the proactive reduction of transfusion transmitted infections. Operational gains can occur at the blood center or hospital, depending on where activities take place.
INTERCEPT offers the following advantages:
Attain two platelet doses from one INTERCEPT kit
Blood centers are able to produce two therapeutic platelet doses from a single INTERCEPT Dual Storage Processing Set, leading to decreased kit costs.
Improved platelet availability, decreased wastage
Unlike bacterial culture detection, INTERCEPT allows for immediate accessibility of platelet units with release of product on day one. Early platelets release provides added flexibility for managing inventory, and enables hospitals to attain fresher platelets.
Avoidance of cost and complexity of bacterial testing
INTERCEPT offers the potential to replace bacterial detection methods with its ability to reduce the risk of bacterial contamination of platelets, and sepsis.
Reduced treatment costs with reduced occurrence of TTI and TA-GVHD
The INTERCEPT Blood System for Platelets reduces transfusion transmitted infectious (TTI) risk, including sepsis.1 It also reduces the risk of transfusion-associated graft-versus-host disease (TA-GVHD).1 This can result in reduced costs associated with treatment, re-calls and follow-up investigations.2
1) The INTERCEPT Blood System for Platelets-Dual Storage (DS) Package Insert, December 18, 2014.
2) Berger K, et al. Onkologie 2013;36:53-59